1. Amoxicillin is not standard care for DFU's. Is mainly respiratory and chest (but not always).
2. How can you make a claim that RCE is clearly evidenced and better than when they have revealed absolutely no data.
3. If you think RCE can somehow push there way into the market of current antibiotics for 'mild infections' in competition with giant pharma companies that pay off doctors, organisations etc, you are delusional. They need to focus on unmet needs or areas where current antibiotics are ineffective. Mild infections and DFU's are neither of these!
Ann: Positive Phase II Data from Clinical Trial of R327 Gel, page-61
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.010(3.33%) |
Mkt cap ! $89.39M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 32.0¢ | 30.0¢ | $25.76K | 82.29K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 13550 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 18938 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |